Test Code Bile Frac Bile Acids, Fractionated and Total, Serum
Useful For
Measuring tauro- and glycol-conjugated and unconjugated bile acid constituents in serum specimens
Monitoring patients receiving bile acid therapy, such as cholic acid, deoxycholic acid, or ursodeoxycholic acid
Aiding in the evaluation of liver function; evaluation of liver function changes before the formation of more advanced clinical signs of illness such as icterus
Determining hepatic dysfunction as a result of chemical and environmental injury
Indicating hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment
Indicating intrahepatic cholestasis of pregnancy
This assay is not useful for the diagnosis of peroxisomal biogenesis disorders or inborn errors of bile acid metabolism.
Reporting Name
Bile Acids, Fractionated and Tot, SSpecimen Type
SerumOrdering Guidance
This test is useful in diagnosing intrahepatic cholestasis of pregnancy and does not support the assessment of either peroxisomal biogenesis disorders or inborn errors of bile acid metabolism.
For diagnostic testing for peroxisomal biogenesis disorders, order BAIPD / Bile Acids for Peroxisomal Disorders, Serum.
Specimen Required
Patient Preparation: Patient must be fasting for 12 to 14 hours.
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Patient fasting is recommended, but not necessary to proceed with collection. It is at the discretion of the ordering provider.
Specimen Minimum Volume
0.3 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 90 days | |
Ambient | 90 days | ||
Frozen | 90 days |
Reject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Reference Values
Total cholic acid: ≤5.00 nmol/mL
Total chenodeoxycholic acid: ≤6.00 nmol/mL
Total deoxycholic acid: ≤6.00 nmol/mL
Total ursodeoxycholic acid: ≤2.00 nmol/mL
Total bile acids: ≤19.00 nmol/mL
Method Description
Bile acid concentrations in serum are measured by liquid chromatography tandem mass spectrometry stable isotope dilution analysis. Serum is mixed with isotopically labeled internal standards of selected bile acids and then subjected to protein precipitation. Sample preparation is semi-automated using a liquid handler. Reverse-phase liquid chromatography is performed using mobile phases to separate free bile acids, their respective tauro- and glyco-conjugates, and 2 bile acid precursors.(Unpublished Mayo method)
Day(s) Performed
Monday through Friday
TAT: 4 - 9 days
Report Available
3 to 5 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82542
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
BAFS | Bile Acids, Fractionated and Tot, S | 43130-4 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
35796 | Total Cholic acid | 30518-5 |
35797 | Total Chenodeoxycholic acid | 30519-3 |
35798 | Total Deoxycholic acid | 30520-1 |
35799 | Total Ursodeoxycholic acid | 55159-8 |
35800 | Total bile acids | 14628-2 |
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Special Instructions
Testing Algorithm
For more information see Bile Acid-Associated Tests Ordering Guide
Forms
If not ordering electronically, complete, print, and send a Gastroenterology and Hepatology Test Request (T728) with the specimen.